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Abstract
Background: Chronic mercury intoxication is a severe health issue and occurs especially in gold mining
communities. Common chelators used for improving mercury elimination are not everywhere available and
challenged by poor cell wall penetration. This study is part of a feasibility trial and the aim was to gather first
information about the efficacy of the newly developed chelator N,N‘bis-(2-mercaptoethyl) isophthalamide (NBMI)
on chronic mercury intoxication.
Methods: In this three-armed, placebo-controlled randomized trial, 36 miners with mercury urine levels exceeding
15 μg/l were administered 100 mg NBMI, 300 mg NBMI or placebo for 14 days. Levels of mercury in urine [μg/l and
μg/g creatinine] and plasma l were analyzed. Therapeutic effect was assessed using the medical intoxication score
(MIS) and its single health outcomes (e.g. excessive salivation, sleeping problems), fatigue scores, a neuromotoric
test battery (CATSYS) and a neurological outcome (Finger to nose test).
Results: Physical fatigue was significantly decreased in the 300 mg NBMI group compared to the control. Mercury
concentration in urine following 300 mg NBMI treatment was significantly lowered compared to control, however,
this effect was less distinct with adjustment for creatinine.
Conclusion: NBMI showed an effect on physical fatigue and there were indications to positive effects on other
symptoms as well. More comprehensive studies are mandatory to verify the effects of NBMI as a novel tool for
treating mercury intoxications.
Trial registration: ClinicalTrials.gov Identifier: NCT02486289. Date of registration: June 24, 2015.
Keywords: Mercury, Chronic mercury intoxication, Gold mining, NBMI, Chelation therapy
Background
Mercury (Hg) is a highly toxic heavy metal; acute as well
as chronic intoxication can occur. It accumulates in the
body over time and can cause severe damage to kidneys
and neural tissues [1–3]. A recent study determined the
severity of chronic mercury intoxication in terms of dis-
ability weights and found the most severe case of intoxica-
tion to be more serious than severe depression and
quadriplegia [4]. Common chronic intoxication symptoms
are tremor, ataxia of gait, coordination problems, excessive
salivation and sleeping problems [5, 6].
The risk of exposure is especially high in gold pro-
ducing areas, since practices using elemental mercury
are still very common in artisanal small-scale gold
mining (ASGM) [7, 8]. The global number of people
earning their living with ASGM is estimated to be 10
to 16 million in 70 countries [7, 9]. By mixing the
pulverized gold ore with elemental mercury and burn-
ing the so formed amalgam without protection, the
miners are directly exposed by inhalation of the toxic
vapor [10, 11]. This results in increased mercury bur-
den, which is detectable in urine, blood and hair.
Moreover, the proximity of the processing to living
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spaces and lack of awareness for toxic waste disposal
affects not only the miners themselves, but also their
children and communities by food, air, water and soil
pollution [12–14].
There are two common chelating agents in use for
treating mercury intoxication at the moment: the
British Anti-Lewisite derivates 2,3-dimercapto-1-pro-
panesulfonate (DMPS) and dimercaptosuccinic acid
(DMSA). DMSA is approved by the U.S. Food and
Drug administration to treat patients with increased
mercury levels by eliminating lead, but is also used as
an off-label medication for Hg intoxication in North
America. DMPS is approved in Germany and used
across Europe for excreting Hg. However, unfortu-
nately, in many countries where ASGM and the ex-
posure to mercury are widespread, e.g. Ecuador and
Indonesia, neither is available. As the Hg exposure
mainly affects the poorer parts of the population, e.g.
informal miners and their families, there is very little
effort from the private sector to improve the situ-
ation. Nevertheless, as recognized by the Minamata
Convention in 2013, along with prevention, the treat-
ment of Hg intoxication is a paramount task and an
efficacious and available medication much needed.
Several studies described the efficacy on mercury
intoxication of both agents [15–18]. Additionally, a
recent report suggests that DMPS and DMSA do not
form true chelate complex with mercuric ions [19].
Unfavorable stereo-chemical properties allow only one
thiol of the chelators to bind to the metal resulting
in a weaker bond. Thus, there might be possibilities
to further improve the clinical efficacy [19]. On top,
both are charged molecules and, as a result, are not
able to pass the blood brain barrier or effectively
enter cells. Hence, they are not able to extract the
heavy metal directly from brain tissue and within the
cells [20], recent reports even postulates redistribu-
tion of Hg into neuronal tissue [21]. Consequently,
novel approaches for metal elimination are highly
desirable [18].
N,N‘bis-(2-mercaptoethyl) isophthalamide (NBMI)
is a newly developed, lipophilic chelating agent specif-
ically created for complexing inorganic mercury (see
Fig. 1). This field study was embedded in an
explorative trial to test the feasibility for an upcoming,
larger phase-IIb clinical study. These smaller studies
are needed to test outcomes, infrastructure, study
parameters and local circumstances and to avoid
problems in following bigger and more expensive
studies. While its cytoprotective, anti-oxidative prop-
erties and its impact on acute Hg intoxication in rats
are already proven [22–24], the aim of this pilot study
was to gain first knowledge about the efficacy of
NBMI on chronic mercury intoxication in humans.
Methods
Study design
The design of this trial was three-armed, randomized,
double blinded and placebo controlled, consisting of
14 days of treatment and 1 month of follow-up, totaling
to a length of 45 days. It was conceptualized as a pilot
study to gain knowledge about dose and efficacy of
NBMI in mercury-intoxicated individuals. Furthermore,
the feasibility of a future phase-IIb study at the site was
examined. The three arms consisted of two treatment
groups, treated with 100 mg/d NBMI and 300 mg/d
NBMI, respectively, and one placebo group. The subjects
were randomized into the treatment arms in equal num-
bers to obtain a 1:1:1 ratio.
Study population
The study subjects were recruited from the local gold
miner population, since the artisanal miners in the re-
gion of Zaruma/Portovelo, Ecuador, were occupationally
exposed to mercury by handling it directly to amalgam-
ate the gold dust or smelting amalgam to extract the
gold. The miners were approached in collaboration with
local mining organizations and through advertising in
the local community. An informed consent to participate
in the study was obtained from all participants. Urine
samples of 865 interested miners were collected and an-
alyzed for their mercury content. The purpose of this
prescreening was to identify individuals with mercury in
urine values > 15 μg/l for further screening. Of 90 per-
sons with mercury urine levels exceeding the threshold
44 were examined whether they met all the inclusion
criteria and none of the exclusion criteria until the
sample size of 36 was reached (see Appendix and Fig. 2).
For inclusion in the study, subjects had to fulfil the fol-
lowing criteria: an age between 18 and 65 years, urine-
Hg ≥ 15 μg/l, a mercury intoxication medical score of ≥ 5
or ≥ 3 in combination with at least two of the additional
symptoms social nervousness/withdrawal, irritability,
Fig. 1 Chemical structure and basic facts
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memory loss, metallic taste, mental- and physical
fatigue.
All the participants obtained an emergency card with
information on the investigational product, the subject’s
id, the investigator’s name, an emergency number as well
as the name and address of the sponsor. The whole
study was conducted at the Hospital Doctor Humberto
Molina, Zaruma, Ecuador, where direct access to med-
ical emergency care could be provided.
There were no formal sample size calculations for this
study, since the main goal was to explore the feasibility
for a more extensive study. The size of 36 subjects was
chosen as a generally accepted number for a pilot study.
12, 11 and 13 subjects in the treatment groups meant
that the 95% confidence intervals for the difference be-
tween mean values in a NMBI treated group and the
placebo treated group resulted in a length of about 1.6
times the standard deviation.
The three treatment arms differ in participant num-
bers because after randomizing the first 19 individuals,
the necessity to relabel some of the boxes with an ex-
tended expiry date occurred which caused an interrup-
tion of the process. The subjects corresponded to three
blocks of six and the remaining subject was allocated as
an incomplete block. With the arrival of the relabeled
batch, the randomization was continued with new blocks
and caused the inequality in group size. However, this
way the subjects could be randomized and keeping the
blind of the study.
The participants were analyzed according to the treat-
ment arm they were assigned to, regardless of the treat-
ment received. The analysis included all participants
who took at least one dose of medication (NBMI or pla-
cebo) and at least one post baseline assessment of the
MIS. This analysis set corresponds to a modified
intention-to-treat (mITT) analysis set. The per protocol
(PP) analysis set includes only participants without
major protocol violations. This set was used as a sensi-
tivity analysis for the efficacy endpoints.
As shown in Fig. 2, 36 subjects were selected for the
study. 34 (94.4%) participants were administered the
assigned daily dose of the study product on site for all
14 days of treatment. Two subjects took only one cap-
sule for the first 2 and 3 days, respectively, based on an
administrative error in the hospital. The following 12
and 11 days all doses were taken as planned by both
subjects. One of those two subjects had been allocated
to the placebo arm and missed no active dose.
Treatment
For the 14 days of the intervention 100 mg NBMI,
300 mg NBMI or placebo were administered orally to all
patients. The medication comprised of three capsules
per administration for each group, two containing 50 mg
and one containing 200 mg, either of the investigational
product, placebo or a combination of both in the follow-
ing regime:
300 dose arm: two 50 mg NBMI capsules and one
200 mg NBMI capsule,
100 mg dose arm: two 50 mg NBMI capsules and one
200 mg placebo capsule,
Placebo dose arm: two 50 mg placebo capsules and
one 200 mg placebo capsule.
The use of placebo filled dummy capsules ensured the
blinding of the patients. No restriction on medication in-
take in relation to meals was set. Other medication ne-
cessary for the patients’ well-being was allowed to be
administered at the investigator’s discretion, but re-
corded appropriately. The subjects were asked to abstain
from drinking energy drinks containing taurine or glu-
curonolactone and alcohol equivalent to more than two
half-liter bottles per day 72 h prior to the medical as-
sessment visits at day 1, 6 ± 1, 15 and 45 ± 1. Moreover,
for the length of treatment, the subjects were to refrain
Fig. 2 Subject Disposition
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from the intake of herbal medicine, grapefruit or grape-
fruit juice to avoid possible drug interactions. As the use
of mercury in mining is banned in Ecuador no restric-
tion to working in the mines were made.
Randomization and assignment to treatment groups
Upon enrolment, each participant was assigned a con-
secutive number. The subjects were allocated to the
treatment arms (100 mg/d, 300 mg/d or placebo) at a ra-
tio of 1:1:1. For this purpose, a randomization list was
created with the subject numbers using the R system
and the subjects were allocated to the three arms in
blocks of six.
Blinding
At the start of the treatment, the participants were handed
out numbered boxes with the capsules corresponding to
their subject number. Each participant received the same
number of blisters, either filled with NBMI, placebo cap-
sules or both. The boxes and the blisters containing the
investigational product and/or placebo were labelled with
a subject number by an external packaging company to
ensure the blinding of the investigators.
Treatment compliance
The treatment compliance was controlled and docu-
mented by the use of investigational product account-
ability logs. In those logs the date and quantities of
study products received, dispensed to and used by each
subject and products returned and destroyed at the end
was recorded. All administration of the study drug was
supervised, and each participant received the daily dose
at the clinic. The recorded data was verified by the study
monitor during the study’s process and at the end of the
follow up, all investigational products used or returned
were accounted for.
Outcomes
The main aim of this study was to generate explorative
and descriptive data as there is no consistent method for
efficacy assessment or guideline for treatment of mer-
cury intoxication. No formal primary efficacy endpoint
was predetermined, and the outcomes were specified as
differences in comparison to baseline values and the pla-
cebo treated subjects. As described in previous reports,
the following characteristics were examined: the mercury
intoxication medical score (MIS) and its individual com-
ponents [5]. Moreover, a panel of neuro-motoric func-
tions (CATSYS) [25], mental and physical fatigue score
[17], tremor (finger-to-nose test) [6] and mercury values
in plasma and urine were analyzed.
Biomonitoring
The samples for analyzing the mercury concentration in
plasma and urine were taken at day 1 (pre-dose), 15 and
45 and sent to the qualified laboratory ALS Scandinavia
AB in Luleå, Sweden for analyzing.
Medical intoxication score
The medical intoxication score (MIS) is a tool created for
identifying mercury intoxication in patients. It is a ten-
point score which is assessed through medical examin-
ation, neuromotoric tests and an anamnestic questionnaire
[3, 5, 6]. The items consist of excessive salivation, tremor
at work, sleeping problems, bluish discoloration of gingiva,
ataxia, dysdiadochokinesia as much as a heel-to-shin test,
a match box test, a pencil tapping test and additionally a
dipstick test for Proteinuria. Each one can have an
assigned value of 0 or 1, depending on whether the symp-
tom is absent (0) or present (1) or whether the test result
is negative (0) or positive (1). The mercury intoxication
medical score is the sum of the items’ values.
In this study, a change in the score and the value of its
individual items compared to baseline assessment was used
as an efficacy parameter. Accordingly, the change value for
the score ranges from − 10 (maximal improvement of
symptoms) to 7 (maximal worsening of symptoms), since
the least score for subject inclusion is 3. The change value
for the individual items can be − 1 (for worsened condi-
tion), 0 (for unchanged condition) and 1 (for improved
condition). The mercury intoxication medical score was
assessed at screening, visit day 15 and visit day 45.
Mental and physical fatigue score
This score consists of 13 items of which 8 describe phys-
ical fatigue and 5 concern mental fatigue [26]. The items
were assessed in five categories with score values from 0
to 3: “better or much better than usual” (0), “same as
usual” (1), “worse than usual” (2) and “much worse than
usual” (3). This means, the higher the score, the worse the
fatigue. The achievable score values were 0–15 for mental
fatigue and 0–24 for physical fatigue. Items are on a rela-
tive scale to baseline, which has by definition a value of 1
(“same as usual”) for each item, resulting in a mental fa-
tigue score of 5 and a physical fatigue score of 8. The score
was assessed at day 2–13, day 15 and 45 of follow up.
For statistical analysis, a fixed model for repeated mea-
sures was fitted to the endpoints mental fatigue score
and physical fatigue score. All results from day 2 to 15
were included to estimate the change from usual for
each day assessed. The comparison of the NBMI treat-
ment groups with the placebo group is based on the
change from baseline on day 15.
A sensitivity analysis was performed for the results of
the statistical examination based on non-parametric tests
(Wilcoxon–Mann–Whitney test), because diagnostic
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tests and scrutiny of the model residuals hinted at a vio-
lation of the assumption of normality.
Neuromotoric test battery CATSYS
To record neurological symptoms caused by mercury in-
toxication objectively, a common computerized test sys-
tem for measuring motoric skills was used (CATSYS). It
assesses hand coordination, reaction time, postural
tremor and postural stability (www.catsys.dk) [27] and
was already successfully used to measure the effects of
chronic mercury exposure [25, 28, 29]. The tremor in-
tensity was statistically analyzed for differences between
the treatment arms.
A set of performance indices available for the CATSYS
was calculated. The resulting index values were refer-
enced and compared to the performance of a large
sound population given by the company [27]. These in-
dices evaluate the tests for tremor intensity and
frequency, sway characteristics as much as the test for
reaction time and the tests for hand coordination skills.
The instructions for the CATSYS state, that an index
value of 1 corresponds to the performance of a healthy
population. Index results strongly deviating from 1
signify an abnormal performance.
Each participant received an individual instruction and
demonstration of the tests by the investigator and was
subsequently examined for about 15 min.
Finger-to-nose test
The finger-to-nose test detects tremor and can take on
following values: Absent (0), slight (1) and moderate to se-
vere (2) [30]. The baseline was assessed at day 1 and com-
pared to the results assessed at day 15 and 45 of follow up.
Statistical methods
Only descriptive statistics have been used to present all
efficacy variables. Continuous variables were summa-
rized with sample size, median, minimum and maximum
value. Categorical data are shown in frequency tables
with number of subjects, frequency and percentage of
occurrence. Individual data were presented in subject
listings. When applicable, point estimates, together with
their 95% confidence intervals have been presented.
The results of the two NBMI treatment groups were
separately compared with the placebo group on day 15.
To test for differences between the groups, the
ANCOVA method, adjusting for baseline level, was used
for parametric distributed characteristics, while the
Wilcoxon–Mann–Whitney test was used for non-
parametric results. Using the mixed model repeated
measures method, a model was fitted to the daily mea-
sures of fatigue scores, mental and physical fatigue, in-
cluding all results of days 2 to 15 to estimate the mean
change from usual of fatigue at each day. The
comparison between the groups treated with NBMI and
the one treated with placebo is based on the change
from usual on day 15. This change was individually cal-
culated as the difference of baseline values and the
values on day 15 or day 45 and the groups analyzed for
distinctions in the change values. The initial model was
fitted using an unstructured covariance between re-
peated measures. If convergence failed, the following co-
variance structures were tested in the given order until
convergence was reached: Unstructured, Heterogeneous
Toeplitz, Heterogeneous autoregressive, Toeplitz,
Autoregressive.
All assessed data were included in the statistical sum-
mary and missing data were not imputed. All statistical
analyses were performed using the version 9.4 of the
SAS® software.
Safety assessment
Adverse events were identified by spontaneous reports
from the subjects, observations by the investigators or
the medical personnel or through elicitation based on
non-leading questions by the study personnel. All ad-
verse events were recorded in the case report files along
with a diagnosis, when available, or signs and symptoms,
start and stop date and time, intensity (mild, moderate
or severe), a causal relationship with NBMI (probable,
possible or not related). If applicable, the action taken to
handle symptoms and its outcome were recorded as
well. Blood samples were collected for the examination
of clinical chemistry and hematology and sent to a la-
boratory at screening and on days 1,6,15 and 45. On the
same days, a full physical examination was done to con-
trol the vital signs and the general condition as well as
the pulmonic, the cardiovascular, the abdominal and the
neurological state of the participants.
Ethics
The study protocol and study informed consent forms
(ICF) were submitted to the Institutional Review Board
(IRB) of the Universidad de San Francisco de Quito,
Diego de Robles y Vía Interoceánica, Quito, Ecuador, for
review. After requested revisions, the study protocol and
ICF were approved in writing on 26 May 2015. The
Regulatory Authorities required revisions and protocol
(amendment 2) and ICF were therefore re-submitted to
the IRB and approved on 27 Jul 2015.
The study protocol was amended once during the
study (amendment 3) to protocol. The amendment,
including ICF was submitted to the IRB and approved
on 30 September 2015.
The study was performed in accordance with the eth-
ical principles that have their origin in the Declaration
of Helsinki and that are consistent with International
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Conference on Harmonisation/Good Clinical Practice
and applicable regulatory requirements on Bioethics.
Results
Participants
The demographics and baseline characteristics of the
participants are shown in Table 1. They were all
Hispanic males. The mean age was 39 years (range:
19–59 years). There was a difference in age distribu-
tion between the groups.
It further summarizes the baseline data about the mer-
cury exposure of the participants. It shows the time
period of exposure through working and living in the
study area, the kind of occupation in the last year and
the frequency of eating fish. The exposure to Hg varied
greatly in individuals.
Table 2 summarizes the median mercury in urine and
plasma values. The groups apparently differed in Hg in
urine baseline levels.
The different scores at screening, day 15 and day 45
are given in Table 3. Mercury intoxication score
At baseline, the placebo group had a slightly lower aver-
age and median MIS than the other groups (see Table 3).
At visit day 15, the majority of all participants experi-
enced a decrease in MIS compared to the screening day.
The mean change was − 3.2 points for the 300 mg NBMI
arm, − 2.2 for the 100 mg NBMI arm and − 2.5 for the
placebo arm, hinting an easing of symptoms in all treat-
ment groups, which stayed constant till day 45. The dif-
ferences between the treatment arms were assessed
Table 1 Subject work exposure and fish consumption
Variable Category NBMI
100 mg
(n = 13)
NBMI
300 mg
(n = 11)
Placebo
(n = 12)
Age (years) Mean 43.6 38.5 33.3
Min 22 26 19
Max 56 59 47
BMI (kg/m2) Mean 28.5 27.7 29.5
Min 21.8 23.1 18.9
Max 36.4 34.4 39.1
Living in the mining
area [years]
Median 22 15 31
Min 3 1.5 1
Max 54 50 47
Working with
mercury [years]
Median 15 5 12
Min 1 1.5 0.5
Max 20 30 40
Smelting amalgam to
recover the gold
(Yes/No)
Yes 13 (100.0%) 7 (63.6%) 9 (75.0%)
Handling mercury to
extract the gold from
the ore, but no
smelting (Yes/No)
Yes 6 (46.2%) 4 (36.4%) 3 (25.0%)
Smelting gold /
gold buyer (Yes/No)
Yes 0 (0%) 2 (18.2%) 2 (16.7%)
Another job or no job
(Yes/No)
Yes 0 (0%) 2 (18.2%) 1 (8.3%)
Fish Consumption At least once
a week
9 (69.2%) 6 (54.5%) 8 (66.7%)
Never or less
than once
a week
4 (30.8%) 5 (45.5%) 4 (33.3%)
Table 2 Summary of the mercury in urine and plasma values at
screening, day 15 and day 45
NBMI 300 mg
(n = 11)
NBMI 100 mg
(n = 13)
Placebo
(n = 12)
Mercury in urine [μg/l]a
Screening 26.5 (4.22–321.0) 39.1 (12.6–160.0) 9.16 (1.7–230.0)
Day 15 18.5 (2.1–131) 37.7 (8.1–132.0) 13.9 (1.3–161.0)
Day 45 14.2 (1.8–226.0) 39.1 (2.6–96.1) 11.3 (1.3–275.0)
Mercury in urine [μg/g creatinine]a
Screening 62.4 (7.6–773.2) 66.7 (12.4–200) 18.7 (2.6–488.5)
Day 15 65.2 (2.6–298.0) 64.4 (17.2–241.0) 29.75 (1.8–536.7)
Day 45 34.8 (2.9–1883.3) 53.3 (13.2–340.2) 9.86 (0.4–1797.4)
Mercury in plasma [μg/l]a
Screening 5.8 (1.3–95.9) 6.4 (1.7–25.8) 6.1 (1.4–45.8)
Day 15 6.8 (1.7–64.4) 8.0 (2.6–33.6) 5.1 (1.5–42.9)
Day 45 6.4 (1.8–49.0) 9.3 (1.6–42.2) 5.9 (1.0–90.1)
aShown values are medians. Range is shown in brackets
Table 3 Summary of median scores and ranges at screening,
day 15 and day 45
NBMI 300 mg
(n = 11)
NBMI 100 mg
(n = 13)
Placebo
(n = 12)
Mercury intoxication scorea
Screening 6 (5–8) 6 (4–8) 5 (4–6)
Day 15 3 (1–5) 4 (1–7) 2.5 (0–5)
Day 45 3 (1–5) 4 (2–5) 2.5 (0–4)
Physical fatigue scorea
Screening 8 (8) 8 (8) 8 (8)
Day 15 3 (0–7) 4 (0–8) 6 (0–8)
Day 45 3 (0–8) 4 (0–9) 6 (0–8)
Mental fatigue scorea
Screening 5 (5) 5 (5) 5 (5)
Day 15 4 (0–5) 4 (0–5) 5 (0–5)
Day 45 4 (0–5) 5 (0–6) 4.5(0–5)
CATSYS Indexa
Screening 105 (80–139) 72 (62–129) 89 (59–148)
Day 15 98 (48–144) 95 (29–134) 113 (65–152)
Day 45 106 (61–152) 92 (48–127) 90 (70–15)
aShown values are medians. Range is shown in brackets
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based on the ANCOVA methods, including the baseline
score as a covariate in the model. The change from base-
line is not significantly dependent on the baseline score,
which means that the change values are similar, inde-
pendently from the baseline scores.
The average differences in MIS change between the
NBMI groups and the placebo group on visit day 15
amounts to − 0.69 (95%-CI: -1.80–0.43, not significant)
for the 300 mg dose group and 0.19 (95%-CI: -0.90-1.28,
not significant) for the 100 mg dose group. See the
Appendix for the single score items.
A sensitivity analysis based on the PP analysis set re-
sulted in similar values.
Neuro-motoric test battery (CATSYS)
In the CATSYS test, the left and right hand were evalu-
ated and analyzed separately. The tremor intensity was
additionally statistically tested for differences between
the treatment arms and the placebo arm.
Tremor intensity
The different treatment groups were compared for their
results in tremor intensity. The Wilcoxon–Mann–
Whitney test was used, because the assumption of nor-
mality was violated by some outliers. The examination
of the left-hand tremor intensity indicated a decrease of
tremor in the 100 mg NBMI group compared to pla-
cebo (two-sided p-value = 0.053), but the decrease was
less distinct in the 300 mg NBMI group compared to
placebo (not significant). The sensitivity analysis with
the PP subset led to similar results. The assessment of
the right-hand tremor intensity did not indicate any
statistically evident differences between the treatment
arms. This finding was supported by the sensitivity ana-
lysis with the per protocol subset.
CATSYS performance indices
The interpretation of the performance indices was in-
conclusive, since some of the tests showed results in
contrast to the expectations. In referral to the CATSYS
200 user’s manual, the calculated indices for reaction
time, the rhythmic test, the max frequency test and the
median index for tremor would signify a performance
above average. The CATSYS Index is the average of all
performance indices and given in Table 3.
Mental and physical fatigue scores
Physical fatigue score
The physical fatigue score comprised of 8 items and
therefore each subject had a value of 8 at the screen-
ing. The median scores are shown in Table 3 and
means in Fig. 3. The underlying covariance use for
the mixed model repeated measures for the physical
fatigue score was a heterogeneous Toeplitz covariance
structure. Table 4 shows the mean difference of the
scores at day 15 and baseline after adjustment for the
covariates of the mixed model of repeated measure-
ments and on the right side the difference of the ad-
justed means of the treatment groups and placebo. At
day 15, a mean drop of 56% in the 300 mg NBMI
group, a decrease of 47% in the 100 mg NBMI group
and a 30% drop in the placebo group. The mean dif-
ference in change in physical fatigue score between
the NBMI 300 mg group and placebo was estimated
to − 2.1 and statistically significant. The correspond-
ing mean difference in change between the NBMI
100 mg group and placebo was estimated to − 1.4 (see
Table 4). The sensitivity analysis with the non-parametric
tests led to similar results as presented in this section.
Mental fatigue score
All the participants had per definition a baseline value of
5. On day 15 it showed a decrease in the 300 mg treat-
ment group to 2.8 ± 2.04 (a drop of 44%), to 3.0 ± 2 in
the 100 mg treatment group (a decrease of 40%) and to
4.1 ± 1.56 in the placebo group (a decrease of 18%). The
mixed model repeated measures that converged for this
analysis was the model with a Toeplitz covariance struc-
ture. The model showed mean differences in change to
be − 1.3 for 300 mg NBMI vs. placebo and − 1.1 for
100 mg vs. placebo (see Table 4). The sensitivity analysis
with the non-parametric tests led to similar results.
Change from baseline finger-to-nose test
At baseline assessment, tremor was found in 14 (39%)
persons. Throughout the groups, the symptom levels did
not change in the majority of persons on day 15 com-
pared to baseline. The two treatment groups were tested
against placebo using the Wilcoxon–Mann–Whitney
test. Since the scale is discrete, an exact method based
on the Monte Carlo simulation was used.
The sum of scores was marginally lower for the
300 mg NBMI group compared to the placebo group
(0 vs. 1), however this seems to be accidental. In con-
trast, the sum of scores of the 100 mg NBMI group
is slightly higher (2), but this also is not statistically
significant.
Individual change of mercury levels
Changes of urine-Hg levels adjusted for creatinine
The inter-individual variability was large for this
characteristic (range: 2.63–773.2 μg/g creatinine, see
Table 2). The median values and change values are
shown in Fig. 4. The 300 mg NBMI group showed a
higher average level for mercury in urine, 199.1 μg/g
creatinine, at baseline compared to a level of 84.9 μg/g
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creatinine in the 100 mg NBMI group and 107.8 μg/g
creatinine in the placebo group. The distribution of
the adjusted mercury in urine values was asymmetrical,
thus to compare the change from baseline between the
groups the non-parametric Wilcoxon–Mann–Whitney
test was used. It was applied for the differences be-
tween results of day 15 and day 45 and baseline. The
medians of the measured values are shown in the sum-
mary in Table 2, while Table 5 shows the median of the
individual differences between the values of day 15 and
45 and baseline. The results indicate a lowering of the
adjusted mercury in urine levels for the 300 mg NBMI
group, although this effect is not statistically. The
result of the test of 100 mg NBMI vs. placebo does not
show a difference.
Changes of urine-Hg unadjusted for creatinine
As for the adjusted urine-Hg, the distribution of the
unadjusted urine-Hg was asymmetrical as well and the
Wilcoxon–Mann–Whitney test was used for evalu-
ation. The findings suggest a statistical significant dif-
ference in change at day 15 for 300 mg NBMI vs.
placebo (p < 0.05). There is a change in value for the
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Fig. 3 Overview of mean fatigue scores and change over follow up. The bars show the physical and mental fatigue scores at baseline, Day 15 and
Day 45 stratified by treatment arm. The data is expressed as mean ± SD, the asterisk indicate statistical difference to the placebo group at p < 0.05
Table 4 Statistical analysis of the fatigue scores – adjusted mean
changes from baseline and difference from placebo on day 15
Adjusted change
from baseline
Difference
from Placebo
Treatment N Adj.meana 95%-CIb Adj.meana 95%-CIb p-value
Physical fatigue score
NBMI
100 mg
13 −3.769 [−5.343;
-2.195]
−1.353 [−3.433;
0.728]
.2019
NBMI
300 mg
11 −4.454 [−6.049;
-3.042]
−2.129 [−4.156;
-0.102]
.0396*
Placebo 12 −2.417 [−3.777;
-1.057]
–
Mental fatigue score
NBMI
100 mg
13 −2.000 [−3.048;
-0.952]
−1.083 [− 2.432;
0.266]
.1152
NBMI
300 mg
11 −2.182 [−3.335;
-1.029]
−1.265 [−2.698;
0.167]
.0833
Placebo 12 −0.917 [−1.767;
-0.067]
–
The asterisk indicates a statistical difference to the placebo group with p < 0.05
aAdjusted mean score reduction after fitting the daily measured fatigue scores
in a Mixed Model of Repeated Measurements
b95%-Confidence interval
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100 mg group vs. placebo, however, not statistically
significant.
Change of plasma-Hg
To obtain a normal distribution for the plasma Hg
values, the values needed to be log-transformed. Then
the test results from the ANCOVA were transformed
back after the test. Based on the model, at day 15, there
was an average reduction of 13% for the 300 mg NBMI
group, for the 100 mg NBMI group there was a 7% de-
crease and for the placebo group a 9% reduction of
mercury levels in plasma from baseline levels. The differ-
ences in change between the groups were not statistically
significant. The sensitivity analysis of the differences in
change of the plasma Hg was done with the Wilcoxon–
Mann–Whitney test provided consistent results.
Adverse events
No serious adverse events (SAE) occurred in this study
and there was no discontinuation due to adverse events
(AE). The majority of AE were headaches and gastrointes-
tinal events evenly throughout all three groups, so that no
event could be clearly related to NBMI. 47 AE in 19 sub-
jects (52.8%) were reported over the treatment and follow-
up period similar distributed between the treatment arms.
All events are given in a table in the Appendix.
Discussion
NBMI is a chelating agent, which binds to Hg mole-
cules and renders them nontoxic. Nevertheless, it
chemical properties are different from the two com-
mon agents, DMSA and DMPS, as it is lipophilic and
able to enter cells. NBMI is postulated to access the
Hg in deeper departments, while DMSA and DMPS
bind to the free Hg and help to excrete it with urine.
Thus, it is difficult to compare these compounds by
the same standards. As NBMI is mainly excreted
through feces, temporarily raised urine Hg values as
well as a very fast excretion could not be expected.
NBMI forms a very stable chelating complex with Hg
and disables it from reacting within the body. A re-
duced Hg body burden would result in lowering urine
levels and a relieving of symptoms.
This study was designed as a pilot to gather informa-
tion about various outcomes and their value for
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Table 5 Summary of changes from baseline in urine values
Treatment Visit Median p-value*
Mercury in urine [μg/l]
NBMI 100 mg Day 15 −6.4 (− 128.6–76.1) .892
Day 45 −1.5 (− 126.5–22.2) .812
NBMI 300 mg Day 15 −8.2 (− 240.9–0.8) .011
Day 45 −6.0 (− 246.9–6.8) .069
Placebo Day 15 2.7 (−71.9–45.9)
Day 45 0.1 (−74.7–49.3)
Mercury in urine [μg/g creatinine]
NBMI 100 mg Day 15 8.2 (− 135.9–122.8) .849
Day 45 −13.8 (− 140.2–232.5) .894
NBMI 300 mg Day 15 −24.6 (− 475.5–79.0) .091
Day 45 −4.0 (− 463.3–1110.1) .722
Placebo Day 15 1.8 (−407.9–297.1)
Day 45 −5.9 (− 453.7–1557.8)
Results give the median values measured at each time point. Change of
baseline is the difference of the day 15/day 45 value and baseline value in
each individual. The median of calculated differences is shown
*Wilcoxon-Mann-Whitney test for differences in change from baseline
between treatment groups and placebo
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measuring efficacy of NBMI. It is the first trial to assess
the efficacy of this new compound. Despite the small
sample size, a positive effect could be shown.
The most evident effect of NBMI compared to pla-
cebo could be seen on the subjects’ fatigue. In contrast
to the 100 mg NBMI dose, the physical fatigue score
was improved in the 300 mg NBMI group suggesting a
dose-response relationship with a p-value < 0.05 for
the difference to placebo group. As the sample size of
36 was chosen to show a ‘proof of concept’, these sta-
tistically significant results surpassed the expectations.
Some of the fatigue score items improved quickly
within the first days and the effects persisted to day 45.
Of the biomonitoring outcomes, mercury levels in
urine and plasma, only the change in the unadjusted
Hg in urine level for the 300 mg group was statisti-
cally significant (p < 0.05) in comparison to placebo.
However, this effect was not as distinct after adjust-
ing the values for creatinine (p < 0.1). Evaluation of
spontaneous urine samples was challenging due to a
broad inter-individual variability and an inter-group
difference at baseline. Unfortunately, after randomiz-
ing the groups, the baseline urine values of the pla-
cebo group were lower than in the other groups. The
difference occurred probably due to the small sample
size and the broad individual variability. Hence fur-
ther studies will have to include 24-h urine collection
in order to underpin the data on Hg excretion as an-
alyzed in this study. Chemical properties as such as
lipophilicity of NBMI also suggest fecal analysis being
a valuable tool for quantifying Hg excretion.
Plasma Hg levels did not differ between the ana-
lyzed groups. With a high quantity of Hg binding to
albumin whole blood analysis would be mandatory in
further studies. We waived this analysis as the ana-
lytic setup needed was not available at the site, and
transportation was not feasible due to technical con-
straints. Whole blood samples might have been more
conclusive.
There was also no evidence of a treatment effect
on the MIS. The single MIS items proved to be chal-
lenging to compare, since differences between the
groups were already apparent at screening. For ex-
ample, in the 300 mg group 7 persons showed exces-
sive salivation at screening, of which 4 showed an
improvement, while there were none with this symp-
tom in the placebo group. Additionally, the MIS was
designed as a tool for a quick and easy diagnosis of
Hg intoxications in the field and might not be ideal
for efficacy assessment. Some of the neurological
signs assessed in the MIS developed over years of ex-
posure and could be irreversible. Furthermore, the
binary coding of the items might be not sensitive
enough to describe an improving of the symptoms
and a different choice of scaling is advisable. For example:
There was an improving in the matchbox test and the
pencil tapping test throughout all groups and most partic-
ipants reached results above the threshold levels at the
second assessment. This improvement probably occurred
due to a learning effect over repeating the test; therefore,
narrower categories would be helpful to determine differ-
ences in improvement.
In comparison with another study in a similar setting
and DMPS treatment by Drasch et al., the here ob-
tained results are in the same order of magnitude [17].
In both studies, the greatest effect of the chelators
showed in the improved fatigue scores. Additionally, in
the Mt.Diwata population was a first improvement in
neurological symptoms apparent; however, because of
ethical restriction there was no placebo control pos-
sible. Assuming a similar effect size as in our study,
these neurological improvements might also be attrib-
utable to a placebo or, with the pencil tapping test, a
learning effect.
There was another coincidental observation made by
the principle investigator during the study. Some of
the men had problems with erectile dysfunction prior
to the medication that seemed to improve with NBMI.
This is based on oral reports and was not included in
the original design; thus, it was not quantified, it will
be, however, considered in the following studies.
Further two basic factors should be considered when
evaluating the efficacy of the investigational product.
As with DMPS, the treatment period of 14 days might
be too short to see the improving of symptoms and it
could not be expected, that neurological signs and
damages developed over several years can be changed
greatly in that period [17]. Furthermore, in future
studies the dose could be adapted to body weight. The
workers tend to be overweight with a mean BMI of 28
and thus might need a higher dose. The best effect on
fatigue in the 300 mg group could be seen in partici-
pants who have been screened with a lower Hg urine
level (less than 100 μg/g creatinine). The phase 1 study
for NBMI showed that a daily dose of 600 mg is harm-
less in humans; therefore, a further dose escalation is
possible and might result in a greater effect.
Although the use of mercury is legally prohibited
in Ecuador since a couple of month prior to the
study, one cannot rule out the possibility, that some
of the miners and thus the participants are still using
mercury informally, e.g. at their homes. This would
result in a difference in ongoing exposure, as some
miners are only exposed through old tailings while
others handle mercury directly. This could explain
the high outliers in urine values at day 45 and the
newly occurred ataxia of gait in three participants. A
possible solution for this problem would be the
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hospitalization of the participants for the length of
the study to ensure controlled conditions. However,
especially in the prospect of a more extensive study,
hospital stays for all participants would exceed the
local hospitals capacities and the magnify the costs
for researching this orphan drug. A different and
probably more feasible approach to keep the miners
from processing gold ore would be a more restrictive
protocol in combination with a payment for the
miners’ participation. This would reduce exposure
variance within and between the groups and cover
the miners’ loss of income for that period, as some
might depend on it for making a living.
This study is limited by the small sample size of 36,
which needs to be increased to exhaustively prove the
effects shown here. The reported improvement should
be considered indications and need to be reconfirmed
in the next study. Another limitation is the possible
difference in ongoing exposure to mercury, which
could have led to an underestimation of the effects.
Additionally, as mentioned before, the study parame-
ters like length of follow-up, the scale of efficacy vari-
ables need to be adjusted to describe any effects.
The strength of this study is in the extensive set of
possible outcome variables. The task of proving the ef-
ficacy is rather difficult, since there are no standards
for assessing it and no guidelines for treating Hg intox-
ications. It is important to test and define a set of pa-
rameters, which can show an improving condition
through medication resp. Hg removal, e.g. signs of the
neurological damage are probably irreversible and not
viable for efficacy assessment. The insights of this
study will be valuable in upcoming phases.
Moreover, there is a supply gap for treating Hg in-
toxication in many countries and there seems to be too
little effort to close them. As in ASGM, the Hg expos-
ure unfortunately mostly concerns the poorest [31],
thus, the economic interest in improving this situation
is probably too low. A chelating agent which is avail-
able in ASGM countries could be very helpful. Despite
all difficulties, the goal of reducing the health effects of
mercury exposure with prevention and treatment is
important and much needed [11].
Conclusion
Although this study was designed with a small sample
size to test for feasibility, the gained results with 300 mg
NBMI already showed an effect on physical fatigue with
statistical significance and there were indications to posi-
tive effects on other symptoms, like sleeping problems.
Further studies, with a greater sample size, longer
follow-up and possibly higher doses or repetitive treat-
ment periods are needed to verify the positive effects
and their superiority against placebo. A further
approach, including an analysis of feces, is necessary to
quantify and prove the mobilization and excretion of mer-
cury by NBMI. Therefore the outcome variables need to
be improved to define a more suitable efficacy assessment.
Appendix
Inclusion criteria
For inclusion in the study, subjects had to fulfil the
following criteria:
1. Male or female subjects, age between 18 and
65 years, inclusive.
2. Urine-Hg ≥ 15 μg/l.
3. Mercury intoxication medical score sum ≥ 5 [5] or
medical score sum ≥ 3 in combination with at least
two of the following additional symptoms; social
nervousness/withdrawal, irritability, memory loss,
metallic taste, mental- and physical fatigue.
4. Has signed informed consent for participation.
5. Willingness and ability to comply with study proce-
dures, visit schedules, and other instructions regard-
ing the study.
Exclusion criteria
Subjects could not be entered in the study if any of the
following exclusion criteria were fulfilled:
1. A history of any clinically significant disease or
disorder which, in the opinion of the investigator,
may either put the subjects at risk because of
participation in the study, or influence the results or
the subject’s ability to participate in the study.
2. Known or a medical history of renal disorder,
significant renal failure, or high risk of renal failure.
3. Any clinically significant abnormalities in clinical
chemistry or hematology results at the time of
screening as judged by the investigator.
4. Known or suspected neurodegenerative disorder
including but not limited to stroke, polio,
Parkinson’s and Alzheimer’s disease.
5. Known or suspected drug or alcohol abuse.
6. Positive pregnancy test in women.
7. Serious bacterial and chronic viral infection such
as human immunodeficiency virus (HIV) or
hepatitis virus.
8. History of severe allergy/hypersensitivity or on-going
allergy/hypersensitivity, as judged by the investigator
or history of hypersensitivity to drugs with a similar
chemical structure or class to NBMI.
9. History of allergy/hypersensitivity to bisulphites (e.g.
red/white wine).
10. Participation in any other clinical study that
included drug treatment within 3 months of the
first administration of investigational product.
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11. Use of other therapies for mercury intoxication
including metal chelators within 3 months.
12. Investigator considers subject unlikely to comply
with study procedures, restrictions and requirements.
Content of the capsules
NBMI capsules (50 and 200 mg) had the following
content:
Active compound: NBMI.
Dosage form: Oral capsules.
Excipients: Microcrystalline cellulose, magnesium stearate.
Packaging: Blisters.
Placebo capsules (50 and 200 mg) had the following
content:
Active compound: Placebo.
Dosage form: Oral capsules.
Excipients: Microcrystalline cellulose, magnesium stearate.
Packaging: Blisters
Mercury intoxication score items
At screening, except of excessive salivation (33% of the
study population), tremor at work (14%), bluish discol-
oration (33%) and proteinuria (3%), all symptoms were
common (< 50%) among the workers. The distribution
of symptoms in these Ecuadorian miners is described
in detail in a previous paper [32].
Ataxia of gait
All in all, 26 participants (72%) suffered from ataxia of
gait at screening. Only 4 showed an improvement on
day 15, 2 with 300 mg NBMI and 2 with placebo. From
the 10 persons without this sign at screening, 3 (30%)
complained about slight or moderate ataxia of gait at
day 15, 2 in the 100 mg treatment arm and 1 in
300 mg treatment arm.
Bluish discoloration of gingiva
Twelve (33%) subjects showed a discoloration of the gin-
giva at screening. 2 of those, 1 with 100 mg NBMI and 1
with placebo, showed improvement on day 15.
Dysdiadochokinesia
Thirty two (89%) miners showed dysdiadochokinesia at
screening, 9 (82%) in the 300 mg group, 12 (92%) in the
100 mg group and 11 (92%) in the placebo group. At
day 15, 3 (33%) persons showed improvement in the
300 mg treatment arm, 2 (17%) in the 100 mg treatment
arm and 2 (18%) in the placebo arm. In both NBMI
treatment groups, one person showed dysdiadochokine-
sia at day 15, but not at screening.
Excessive salivation
A total of 12 participants showed excessive salivation
at screening, all of them were randomized into the
NBMI treatment arms, 7 (63%) into the 300 mg dose
group and 5 (38%) into the 100 mg dose group. At visit
day 15, of the workers taking in 300 mg NBMI only 3
(27%) remained to show excessive salivation, which
signifies a decrease of 57%, while in the 100 mg NBMI
group 3 (23%) persons still showed this symptom, a de-
crease of 40%. Since no one in the placebo group suf-
fered from excessive salivation at baseline, no
comparison of the rate of improvement was possible.
Heel-to-shin test
Of all participants, 32 (89%) had trouble doing the heel-
to-shin test. Similar proportions showed symptom
improvement with 300 mg NBMI (4 persons; 44%) and
placebo (5 persons; 45%), whereas the 100 mg group
showed less improvement (2 persons; 17%)
Matchbox test
At screening 33 (92%) participants needed > 18 s for
putting all the matches into the box. 58% of these could
do the same test in ≤18 s at day 15. This progress was
found equally in all groups, a marginally higher propor-
tion improved in the placebo group.
Pencil tapping
In total 27 subjects (75%) had ≤45 taps in the pencil-
tapping test at screening. Of these 89% showed an im-
provement to > 45 taps at day 15. This proportion is
similar in both treatment groups and the placebo group.
Proteinuria
Only one subject showed proteinuria at screening, but did
not anymore on day 15 after the 300 mg NBMI treatment.
Sleeping problems at night
In total, 33 (92%) subjects reported sleeping problems at
screening. In the 300 mg group 9 (82%) participants
complained about this symptom, while on day 15 only 2
(18%) remained suffering from it, a decrease of 78%. The
100 mg treatment group similarly showed a decrease of
77%: all 13 participants had sleeping problems at screen-
ing, while only 3 (23%) remained on day 15. In the pla-
cebo group, of 11 (91%) workers had sleeping problems
at baseline and 6 (50%) on day 15, a 45% reduction.
Tremor at work
Five (14%) participants complained about tremor at work
at baseline, all of them belonged to the treatment groups.
In the 300 mg-treatment arm, at the screening 3 partici-
pants perceived tremor, while at visit day 15 none of them
had any tremor at work. Of the 2 persons in the 100 mg
NBMI group, one did not show his symptom at visit day
15. No comparison with the placebo group was possible.
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Table 7 Summary of subjects with any AE by preferred term (safety set)
Number (%) of subjects
Preferred term NBMI 100 mg
(n = 13)
NBMI 300 mg
(n = 11)
Placebo
(n = 12)
Total
(n = 36)
Number of
subjects with
any AE*
6 (46.2%) 5 (45.5%) 8 (66.7%) 19 (52.8%)
Headache 5 (38.5%) 3 (27.3%) 4 (33.3%) 12 (33.3%)
Abdominal
pain upper
1 (7.7%) 1 (9.1%) 2 (16.7%) 4 (11.1%)
Abdominal pain 1 (9.1%) 2 (16.7%) 3 (8.3%)
Diarrhoea 1 (7.7%) 1 (8.3%) 2 (5.6%)
Somnolence 1 (7.7%) 1 (8.3%) 2 (5.6%)
Animal bite 1 (9.1%) 1 (2.8%)
Arthralgia 1 (8.3%) 1 (2.8%)
Back pain 1 (8.3%) 1 (2.8%)
Ear pain 1 (7.7%) 1 (2.8%)
Gastroenteritis 1 (7.7%) 1 (2.8%)
Ingrowing nail 1 (7.7%) 1 (2.8%)
Insomnia 1 (8.3%) 1 (2.8%)
Lip dry 1 (8.3%) 1 (2.8%)
Oropharyngeal pain 1 (8.3%) 1 (2.8%)
Vertigo 1 (8.3%) 1 (2.8%)
Table 6 Variables of the laboratory safety assessments
Clinical chemistry Hematology Urine analysis
Serum (S)-Alanine aminotransferase (ALT) Blood (B)-Hemoglobin (Hb) Urine (U)-Bilirubin
S-Alkaline phosphatase (ALP) Hematocrit U-Creatinine
S-Aspartate aminotransferase (AST) B-Leucocyte differential count (absolute) U-Glucose
S-Albumin B-Leucocyte count U-Protein
S- Bilirubin Mean cellular volume (MCV) U-Hb/erythrocytes
S-Chloride Mean corpuscular hemoglobin content (MCH) U-Ketone
S-Cholesterol Mean corpuscular hemoglobin concentration (MCHC) U-Leucocytes
S-Creatinine B-Platelet count U-Nitrite
S-CRP Reticulocytes U- Urobilinogen
S-Gamma glutamyl transferase (GGT) pH
S-Glucose Specific gravity
S-LDH U-Pregnancy test
S-Phosphate U-Drug screen
S-Potassium
S-Sodium
S-TSH, T3, T4
S- Ca2+, Mg2+, Zn2+, Cu2+, Fe2+ and Se2+*
Urea (blood urea nitrogen)
*Mercury binds to selenium with extraordinarily high affinity. Available evidence indicates that assessments of mercury exposure and tissue levels
need to consider selenium intakes and tissue distributions to provide meaningful risk evaluations. Therefore, plasma Se2+ was analyzed to further
characterize the study population and susceptibility to the mercury exposure
Schutzmeier et al. Environmental Health  (2018) 17:15 Page 13 of 15
Additional file
Additional file 1: All analyzed results not provided in the article are
given in the additional file. The tables include summaries of basline
characteristics, biomonitoring values und scores. (PDF 1984 kb)
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